NovoCure Ltd. (NASDAQ:NVCR) shares rose 7.6% during mid-day trading on Friday . The company traded as high as $11.77 and last traded at $11.71, with a volume of 134,346 shares changing hands. The stock had previously closed at $10.88.

NVCR has been the subject of a number of research reports. Wedbush restated an “outperform” rating and set a $30.00 target price on shares of NovoCure in a research report on Wednesday. Zacks Investment Research downgraded shares of NovoCure from a “hold” rating to a “sell” rating in a research report on Friday, May 13th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $28.57.

The stock’s market capitalization is $987.89 million. The firm’s 50-day moving average price is $11.36 and its 200-day moving average price is $14.04.

NovoCure (NASDAQ:NVCR) last announced its quarterly earnings data on Monday, May 9th. The company reported ($0.42) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.33) by $0.09. The business had revenue of $13.10 million for the quarter, compared to the consensus estimate of $23.65 million. Equities analysts expect that NovoCure Ltd. will post ($1.38) EPS for the current fiscal year.

In other NovoCure news, COO Michael J. Ambrogi sold 20,000 shares of the stock in a transaction that occurred on Wednesday, June 8th. The shares were sold at an average price of $12.24, for a total value of $244,800.00. Following the sale, the chief operating officer now directly owns 324,084 shares of the company’s stock, valued at approximately $3,966,788.16. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Several large investors have recently made changes to their positions in the stock. Hartline Investment Corp purchased a new stake in shares of NovoCure during the fourth quarter worth approximately $1,143,000. Century Capital Management LLC purchased a new stake in shares of NovoCure during the fourth quarter worth approximately $2,970,000. Finally, Morgan Stanley purchased a new stake in shares of NovoCure during the fourth quarter worth approximately $9,619,000.

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.